Study Results for IMPAACT P1078 Presented at CROI 2018. IMPAACT Network News.

Published Date:

03/07/2018

Publication:

IMPAACT Network News

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the presentation of the study results and important findings from IMPAACT P1078 (TB APPRISE), a phase IV, randomized, double-blind, placebo-controlled trial to evaluate the safety of immediate versus deferred isoniazid preventive therapy (IPT) among HIV-infected women in high tuberculosis (TB) incidence settings, at the 2018 annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts. 

Access Full Article

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term...

The study is being done to try to determine which factors contribute to the persistence of HIV (how long the virus remains) in...

Read More